3,657 Shares in Hologic, Inc. (NASDAQ:HOLX) Bought by Kovitz Investment Group Partners LLC

Kovitz Investment Group Partners LLC bought a new position in Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 3,657 shares of the medical equipment provider’s stock, valued at approximately $264,000.

A number of other large investors also recently made changes to their positions in HOLX. General Partner Inc. bought a new position in shares of Hologic in the fourth quarter valued at approximately $26,000. Venturi Wealth Management LLC lifted its stake in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC increased its position in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares during the last quarter. Finally, Smithfield Trust Co raised its stake in shares of Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 400 shares during the period. 94.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

HOLX has been the subject of several recent research reports. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a report on Friday. William Blair restated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Morgan Stanley reduced their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Royal Bank of Canada dropped their price objective on Hologic from $75.00 to $70.00 and set a “sector perform” rating on the stock in a report on Friday. Finally, Raymond James reaffirmed an “outperform” rating and set a $71.00 target price (down previously from $90.00) on shares of Hologic in a report on Friday. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Hologic presently has a consensus rating of “Hold” and an average target price of $81.15.

Hologic Price Performance

HOLX opened at $54.16 on Friday. Hologic, Inc. has a 12-month low of $52.12 and a 12-month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a 50-day moving average price of $60.28 and a 200-day moving average price of $69.26. The stock has a market capitalization of $12.15 billion, a P/E ratio of 17.09, a PEG ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period last year, the firm earned $1.03 earnings per share. Equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.